Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer - experience from a prematurely closed phase II study

被引：8
|
作者：
Raez, LE [1 ]
Rosado, MF [1 ]
Santos, ES [1 ]
Reis, IM [1 ]
机构：
[1] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Div Hematol Oncol, Miami, FL 33136 USA
来源：
LUNG CANCER | 2004年 / 45卷 / 01期
关键词：
D O I：
10.1016/j.lungcan.2004.01.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：131 / 132
页数：2
相关论文
共 50 条
  • [1] Irinotecan and docetaxel as first-line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer.
    Raez, LE
    Rosado, M
    Santos, ES
    Hamilton, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 677S - 677S
  • [2] Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer -: A phase II study
    Cao, MG
    Aramendía, JM
    Salgado, E
    Aristu, J
    Monje, RM
    Algarra, SM
    Ordoñez, JM
    Brugarolas, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (05): : 480 - 484
  • [3] A Prospective Phase I / II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB / IV Non-Small Cell Lung Cancer
    Kroeber, Vinzenz
    Nagel, Sylke
    Schuette, Wolfgang
    Blankenburg, Thomas
    CASE REPORTS IN ONCOLOGY, 2014, 7 (02): : 435 - 443
  • [4] A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
    F M Wachters
    H J M Groen
    B Biesma
    F M N H Schramel
    P E Postmus
    J A Stigt
    E F Smit
    British Journal of Cancer, 2005, 92 : 15 - 20
  • [5] A phase II study of pemetrexed and gemcitabine plus bevacizumab as first-line chemotherapy for elderly patients with stage IIIb/IV non-small cell lung cancer
    Blakely, L.
    Schwartzberg, L. S.
    Schnell, F. M.
    Sabbath, K. D.
    Miller, P. J.
    Stepanski, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment
    Wachters, FM
    Groen, HJM
    Biesma, B
    Schramel, FMNH
    Postmus, PE
    Stigt, JA
    Smit, EF
    BRITISH JOURNAL OF CANCER, 2005, 92 (01) : 15 - 20
  • [7] Docetaxel-irinotecan doublet chemotherapy as first-line therapy for advanced non-small cell lung cancer: A Phase II study
    Shamseddine, A
    Abou Mourad, Y
    Makarem, J
    Kattan, J
    Farhat, F
    Jalloul, R
    Mukaddem, W
    Taher, A
    Chehal, A
    Ghosen, M
    LUNG CANCER, 2005, 49 : S269 - S269
  • [8] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer
    Stinchcombe, Thomas E.
    Buzkova, Petra
    Choksi, Janak
    Taylor, Mark
    Bakri, Kamal
    Gillenwater, Heidi
    Tynan, Maureen
    Mears, Andrea
    Jones, Paul E.
    Socinski, Mark A.
    LUNG CANCER, 2006, 52 (03) : 305 - 311
  • [9] Preliminary results of a phase II study with weekly docetaxel as second line chemotherapy in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer
    Rossil, D
    Graziano, F
    Alessandroni, P
    Fedeli, SL
    Fedeli, A
    Catalano, V
    Giordani, JP
    Baldelli, AM
    Catalano, G
    ANNALS OF ONCOLOGY, 2000, 11 : 10 - 10
  • [10] A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer
    Matsui, K
    Hirashima, T
    Nitta, T
    Kobayashi, M
    Ogata, Y
    Furukawa, M
    Kudoh, S
    Yoshimura, N
    Mukohara, T
    Yamauchi, S
    Shiraishi, S
    Kamoi, H
    Negoro, S
    Takeda, K
    Nakagawa, K
    Takada, M
    Yana, T
    Fukuoka, M
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 181 - 187
12345